NeuTec Pharma Ltd.

In early 2006, we noted in this space that in-licensing on the part of specialty pharmaceutical start-ups was rising relative to Big Pharma’s in-licensing rate, with specialty pharmas even out-competi

2006’s most intriguing Series As reflect VCs’ continued emphasis on risk reduction through re-profiling in biotech, and big gains in funding for diagnostics and device start-ups. By Christopher Morris

M&A is competitive, and not all subjects are willing ones. Senior executives at Novartis, Big Pharma's number two acquirer, describe their system for identifying acquisition targets, understanding the

Tracking the progress of a group of biotechs founded in the late ’90s yields some important lessons for today’s entrepreneurs. Nancy Dvorin and Melanie Senior Laying out a strategy is one thing; execu